FDA Approves Lutathera for Some Gastro and Pancreatic Cancers

Share this content:
FDA Approves Lutathera for Some Gastro and Pancreatic Cancers
FDA Approves Lutathera for Some Gastro and Pancreatic Cancers

FRIDAY, Jan. 26, 2018 (HealthDay News) -- Lutathera (lutetium Lu 177 dotatate) is the first radioactive drug to be approved by the U.S. Food and Drug Administration to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), the agency said Friday in a news release.

"GEP-NETs are a rare group of cancers with limited treatment options after initial therapy fails to keep the cancer from growing," Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence, said in a statement. "This approval provides another treatment choice for patients with these rare cancers."

The drug was evaluated in two clinical studies involving more than 1,400 patients. Survival with no signs of disease progression was longer for participants who received the drug than among those who didn't.

Lutathera's most common side effects included lymphopenia, high enzyme levels, vomiting, nausea, hyperglycemia, and hypokalemia. More serious adverse reactions could include myelosuppression, secondary myelodysplastic syndrome and leukemia, renal toxicity, hepatotoxicity, and infertility, the FDA said.

The drug is produced by the French firm Advanced Accelerator Applications.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

High Success Rates for Mitral Valve Repair With Robotic Surgery

High Success Rates for Mitral Valve Repair With ...

Minimally invasive surgery linked to fewer discharges to facility, one day less in hospital vs conservative sx

Tattoo-Linked Complications ID'd in Immunosuppressed Female

Tattoo-Linked Complications ID'd in Immunosuppressed Female

Inflammatory myopathy identified in woman with cystic fibrosis on long-term immunosuppressants

Rates of Cardiac Stress Testing Down but Still Higher in CKD

Rates of Cardiac Stress Testing Down but Still ...

Decline in rates of cardiac stress testing in Medicare beneficiaries aged ≥66 years from 2008 to 2012

is free, fast, and customized just for you!




Already a member?

Sign In Now »